Related references
Note: Only part of the references are listed.A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
Peter M. Wilson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
Cheng-Jung Lai et al.
CANCER RESEARCH (2010)
The Microtubule-associated Histone Deacetylase 6 (HDAC6) Regulates Epidermal Growth Factor Receptor (EGFR) Endocytic Trafficking and Degradation
Ya-Sheng Gao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells
Qun Zhou et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes
Zhibin Wang et al.
CELL (2009)
Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
Michaela S. Banck et al.
CLINICAL CANCER RESEARCH (2009)
A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
Marwan G. Fakih et al.
CLINICAL CANCER RESEARCH (2009)
Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells
Estrella Mariel Levy et al.
INNATE IMMUNITY (2009)
Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells
William Fazzone et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond
Vadivel Ganapathy et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Genetic prognostic and predictive markers in colorectal cancer
Axel Walther et al.
NATURE REVIEWS CANCER (2009)
A sweet new role for EGFR in cancer
Jeffrey A. Engelman et al.
CANCER CELL (2008)
Survival of cancer cells is maintained by EGFR independent of its kinase activity
Zhang Weihua et al.
CANCER CELL (2008)
Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival
Veerle F. Casneuf et al.
CANCER INVESTIGATION (2008)
Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2
Yi-Chu Lin et al.
CANCER RESEARCH (2008)
Post-translational control of Sp-family transcription factors
J. S. Waby et al.
CURRENT GENOMICS (2008)
HDACs and HDAC inhibitors in colon cancer
John M. Mariadason
EPIGENETICS (2008)
Attenuation of c-Jun and Sp1 expression and p300 recruitment to gene promoter confers the trichostatin A-induced inhibition of 12(S)-lipoxygenase expression in EGF-treated A431 cells
Ching-Jiunn Chen et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
HDAC inhibition upregulates the expression of angiostatic ADAMTS1
Chia-Wei Chou et al.
FEBS LETTERS (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
The complex language of chromatin regulation during transcription
Shelley L. Berger
NATURE (2007)
Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells
Xiao-Dan Yu et al.
CANCER JOURNAL (2007)
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation
Chunrong Yu et al.
CLINICAL CANCER RESEARCH (2007)
Mechanisms of egfr gene transcription modulation:: Relationship to cancer risk and therapy response
Burkhard Brandt et al.
CLINICAL CANCER RESEARCH (2006)
Histone deacetylase 3 (HDAC3) and other class IHDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer
AJ Wilson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer
N Normanno et al.
GENE (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
HIF-1α induces genetic instability by transcriptionally downregulating MutSα expression
M Koshiji et al.
MOLECULAR CELL (2005)
Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition
X Tong et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Combining EGFR inhibitors with radiation or chemotherapy: Will preclinical studies predict clinical results?
PM Harari et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck
BM Helmke et al.
ORAL ONCOLOGY (2004)
Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of anglogenesis factors
Y Sasakawa et al.
BIOCHEMICAL PHARMACOLOGY (2003)
The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors
CA Ritter et al.
SEMINARS IN ONCOLOGY (2003)
Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells
JA Ewald et al.
EXPERIMENTAL CELL RESEARCH (2003)
Sodium butyrate inhibits cell growth and stimulates p21(WAF1/CIP1) protein in human colonic adenocarcinoma cells independently of p53 status
H Kobayashi et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2003)
Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis
L Rössig et al.
CIRCULATION RESEARCH (2002)
SGLT gene expression in primary lung cancers and their metastatic lesions
N Ishikawa et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2001)
Share Paper
